
Cantargia Q1 2024 - Notable Cost Reductions

Redeye comments on Cantargia's Q1 report. The main thing that stands out is the great Q/Q cost reduction. There has also been developments in inflammatory diseases relevant for CAN10.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Cantargia Q1 2024 - Notable Cost Reductions](#)